FAPI-PET value for the initial screening of pancreatic and biliary cancers (FAPDIG Study)
Key facts
- Where
- Lyon, Montpellier Cedex 5 és Talence, FranciaországSee the 3 sites
- Phase
- 2. fázis
Where in Franciaország
- Centre Leon BerardLyon, FranciaországTaking people
- Institut Regional Du Cancer De MontpellierMontpellier Cedex 5, FranciaországTaking people
- Centre Hospitalier Universitaire De BordeauxTalence, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire De Bordeaux
- Trial code
- EU 2024-517270-23-00
- Record updated
- 2026. augusztus 14.
- Original description
To estimate the proportion of patients who present an appropriate change of TNM classification following the addition of 68Ga-FAPI-46 PET-CT to the reference examinations, during the initial staging of pancreatic and bile duct cancers eligible for curative treatment. Each type of cancer will be studied (analyzed) separatelyRead full original descriptionShow less
"Diagnostic value of 68Ga-FAPI-46 PET/CT in the initial work-up of pancreatic and biliary cancers eligible to a curative treatment" "FAPDIG"
To estimate the proportion of patients who present an appropriate change of TNM classification following the addition of 68Ga-FAPI-46 PET-CT to the reference examinations, during the initial staging of pancreatic and bile duct cancers eligible for curative treatment. Each type of cancer will be studied (analyzed) separately
Inclusion: Population 1: De novo pancreatic adenocarcinoma (pathological evidence) or strong suspicion of de novo pancreatic adenocarcinoma on imaging - Immediately resectable, borderline or locally advanced, potentially requiring curative treatment and non-metastatic (M0), according to reference staging; Population 2 : De novo cholangiocarcinoma (pathological evidence) or strong suspicion of de novo cholangiocarcinoma on imaging - Eligible for curative treatment and non-metastatic (M0), according to according to reference staging; Age >18 years at the time of signing the informed consent; Patient affiliated to a social security system; Free and informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Exclusion: History of other active cancer; Tumor M+ or with suspicion of distant metastasis on standard staging; Person deprived of liberty by judicial or administrative decision; Person in an emergency situation; Exclusion period from another protocol; Neoadjuvant treatment; Pregnant or breastfeeding woman; Person under legal protection (guardianship or curatorship); Person unable to personally give consent.